Monopar Therapeutics (MNPR) begins rolling NDA for ALXN1840 in Wilson disease
Rhea-AI Filing Summary
Monopar Therapeutics Inc. has begun a rolling submission of a New Drug Application to the U.S. Food and Drug Administration for ALXN1840 (tiomolibdate choline), a first-in-class albumin tripartite complex activator being developed to treat Wilson disease.
The FDA has authorized this rolling process and the first sections of the application have been submitted. In a pivotal Phase 3 trial, ALXN1840 met its primary endpoint, showing rapid and sustained copper mobilization significantly greater than standard of care over 48 weeks. Across the clinical development program, durable clinical improvement and favorable tolerability were observed over 645 patient-years in 266 patients. ALXN1840 holds Fast Track, Orphan Drug and Rare Pediatric Disease designations, which provide the potential, at the time of NDA approval, to receive a pediatric Priority Review Voucher.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Wilson disease prevalence: 1 in 30,000 people worldwide
Phase 3 trial duration: 48 weeks
Patients in ALXN1840 program: 266 patients
+1 more
4 metrics
Wilson disease prevalence
1 in 30,000 people worldwide
Approximate global prevalence of Wilson disease
Phase 3 trial duration
48 weeks
Period over which ALXN1840 showed greater copper mobilization than standard of care
Patients in ALXN1840 program
266 patients
Total patients in the ALXN1840 clinical development program
ALXN1840 follow-up exposure
645 patient-years
Total follow-up across the ALXN1840 clinical development program
Key Terms
rolling submission, New Drug Application, Rare Pediatric Disease, Priority Review Voucher, +1 more
5 terms
rolling submission regulatory
"initiated the rolling submission of a New Drug Application"
A rolling submission is a regulatory filing process where a company sends portions of its application to health authorities as each section is completed, rather than waiting to submit the entire package at once. For investors, this can shorten the time to review and potential approval and reduces the risk of a single big setback—think of it like mailing chapters of a manuscript to an editor as they’re finished so feedback and progress happen sooner.
New Drug Application regulatory
"rolling submission of a New Drug Application ("NDA") to the U.S. Food"
A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.
Rare Pediatric Disease regulatory
"ALXN1840 received Rare Pediatric Disease ("RPD") designation by the FDA"
A rare pediatric disease is a serious medical condition that primarily affects children and occurs so infrequently that only a small number of patients exist. Investors care because treatments for such conditions often get special regulatory incentives—think of government fast lanes and rewards for developers—making smaller markets potentially profitable due to pricing power, shorter development timelines, and reduced competition, much like a niche product that receives government-backed advantages.
Priority Review Voucher regulatory
"potential, at the time of NDA approval, to receive a pediatric Priority Review Voucher"
A priority review voucher is a transferable regulatory incentive that lets a company move a future drug or device application to the front of the review line, shortening the review period by several months. For investors it matters because the voucher can speed up market access for a high-value product or be sold to other companies for significant cash, acting like a tradable fast-pass that can accelerate revenue or create immediate financial upside.
albumin tripartite complex medical
"first-in-class albumin tripartite complex ("ATC") activator for the treatment"
An albumin tripartite complex is a three-part molecular assembly in which human serum albumin—an abundant blood protein—carries two other attached components, such as a therapeutic molecule and a helper tag. For investors, this matters because using albumin as a transporter can act like a slow-release backpack, keeping drugs in circulation longer, improving delivery to target tissues and reducing dosing frequency, which can boost a drug candidate’s commercial prospects and pricing power.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Monopar Therapeutics (MNPR) announce regarding ALXN1840?
Monopar Therapeutics initiated a rolling New Drug Application submission to the U.S. FDA for ALXN1840 in Wilson disease, with the agency authorizing this rolling process and the company already having submitted the first completed sections of the application.
What is ALXN1840 and how does it work in Wilson disease for MNPR?
ALXN1840 is a first-in-class albumin tripartite complex activator under investigation for Wilson disease. It rapidly mobilizes and tightly sequesters excess copper, forming stable complexes that limit oxidative damage, block copper transport across the blood–brain barrier, and increase fecal copper excretion.
Which FDA designations has ALXN1840 received for Monopar Therapeutics (MNPR)?
ALXN1840 has Fast Track, Orphan Drug and Rare Pediatric Disease designations from the FDA. The Rare Pediatric Disease designation provides Monopar with the potential, at the time of NDA approval, to receive a pediatric Priority Review Voucher.
What clinical data support ALXN1840 in Wilson disease for MNPR investors?
In a pivotal Phase 3 trial, ALXN1840 met its primary endpoint, showing rapid, sustained copper mobilization significantly greater than standard of care over 48 weeks. Across the program, durable clinical improvement and favorable tolerability were seen over 645 patient-years in 266 patients.
How common is Wilson disease targeted by Monopar Therapeutics (MNPR)?
Wilson disease is described as a rare genetic disorder affecting approximately 1 in 30,000 people worldwide. It involves toxic copper accumulation in the liver, brain and other organs, leading to progressive and potentially fatal outcomes if not treated.
What other programs are in Monopar Therapeutics (MNPR) pipeline besides ALXN1840?
Monopar is also developing a radiopharmaceutical portfolio, including MNPR-101-Zr in Phase 1 for imaging advanced cancers, and MNPR-101-Lu (Phase 1a) and MNPR-101-Ac (late preclinical) for the treatment of advanced cancers.